BMRN — Biomarin Pharmaceutical Balance Sheet
0.000.00%
- $10.23bn
- $9.40bn
- $2.85bn
- 97
- 71
- 57
- 89
Annual balance sheet for Biomarin Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,065 | 1,014 | 1,292 | 1,074 | 1,138 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 448 | 373 | 461 | 634 | 661 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,342 | 2,274 | 2,751 | 2,956 | 3,232 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,090 | 1,082 | 1,114 | 1,112 | 1,077 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 5,848 | 6,003 | 6,375 | 6,842 | 6,989 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 493 | 540 | 589 | 1,177 | 607 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,742 | 1,733 | 1,772 | 1,890 | 1,331 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 4,106 | 4,271 | 4,603 | 4,952 | 5,658 |
| Total Liabilities & Shareholders' Equity | 5,848 | 6,003 | 6,375 | 6,842 | 6,989 |
| Total Common Shares Outstanding |